electroCore, Inc. - ECOR STOCK NEWS

electroCore, Inc. (Nasdaq: ECOR) announced its participation in the HC Wainwright Virtual 22nd Annual Global Investment Conference from September 14-16, 2020. The company will present on September 16, 2020, from 1:30-1:50 PM EDT. Interested parties can access a live webcast through the Investors section of the company's website. electroCore specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation therapy for conditions such as cluster headaches and migraines.

electroCore, Inc. (Nasdaq: ECOR) announced the publication of a study in Brain Stimulation demonstrating that non-invasive vagal nerve stimulation (nVNS) significantly decreases brain activity related to trauma in patients without PTSD. Conducted on 19 subjects, the study showed that nVNS led to critical improvements, highlighting its potential utility in treating psychiatric disorders like PTSD. The treatment is a promising alternative to existing therapies, which often have limitations. The research was sponsored by DARPA and further studies are anticipated.

electroCore (NASDAQ:ECOR) will present at the LD 500 investor conference on September 3rd at 6:20 AM PST / 9:20 AM EST, showcasing its unique bioelectronic medicine solutions. CEO Dan Goldberger will address the audience during this virtual event, which runs from September 1st to 4th. The conference provides a platform for engaging with investors interested in microcap companies. electroCore focuses on non-invasive vagus nerve stimulation, targeting conditions like migraine and cluster headaches.

electroCore (Nasdaq: ECOR) announced a Voluntary ex-ante Transparency Tender Notice published by NHS England, naming it the sole supplier of non-invasive vagus nerve stimulation therapy. This contract provides additional funding for gammaCore therapy to treat cluster headaches, running from October 1, 2020, to March 31, 2021, with a potential 3-year extension. Iain Strickland highlighted NHS England's commitment to providing cost-effective treatments. gammaCore is the only medical technology recommended by NICE for cluster headaches, fulfilling an essential patient need.

electroCore, a bioelectronic medicine company, received Emergency Use Authorization for gammaCore Sapphire CV to treat asthma exacerbations in COVID-19 patients. The company reported net sales of $753,000 for Q2 2020, slightly exceeding guidance, and reduced net cash burn to $5.2 million. Operating expenses fell by 50% year-over-year. The company strengthened its balance sheet by raising $10.3 million post-quarter, leading to pro forma cash of $29.2 million. Key revenue channels showed signs of recovery, with total operating expenses significantly reduced from $12.7 million in Q2 2019.

electroCore, Inc. (Nasdaq: ECOR) will announce its financial results for the second quarter ended June 30, 2020, on August 13, 2020, after market close. A conference call will take place at 4:30 PM Eastern Time to discuss the results and address questions. The company, focused on bioelectronic medicine, aims to enhance patient outcomes with its non-invasive vagus nerve stimulation therapy targeting conditions like cluster headaches and migraines.

electroCore (Nasdaq: ECOR) announced the availability and pricing of its gammaCore Sapphire™ CV non-invasive vagus nerve stimulation (nVNS) therapy under Emergency Use Authorization (EUA) for treating adults with known or suspected COVID-19 and asthma-related breathing difficulties. Starting July 31, 2020, the therapy will be priced at $1,250, down from the list price of $1,750. Premier Pharmacy Services will support distribution, and electroCore plans to establish a telehealth option for order fulfillment.

electroCore, Inc. (Nasdaq: ECOR) announced the publication of a paper in Cephalalgia, detailing non-invasive vagus nerve stimulation (nVNS) as a beneficial treatment for primary headache disorders. The narrative review supports nVNS as effective for acute and preventive treatment of cluster headaches and migraines. Key opinion leaders expressed optimism that the findings will enhance awareness of gammaCore™, an nVNS device. The press release underscores electroCore’s commitment to advancing non-invasive therapies for headache management.

electroCore has provided an operating update, revealing a cash balance of $18.9 million at the end of Q2 2020. Despite the COVID-19 pandemic impacting their business, they reported revenue between $730,000 and $750,000, slightly exceeding Q1 performance. The company received an Emergency Use Authorization (EUA) for gammaCore™ to treat asthma in COVID-19 patients, with ongoing clinical trials in Spain and Pittsburgh. Additionally, orders from the VA/DoD grew, although shipped therapy months dropped due to pandemic disruptions.